Spearheading the cardiovascular precision medicine with innovative medical tools
February 18 @ 09:00 – 09:30 CET
On February 18, we have invited Dr. Tero-Pekka Alastalo, to give a talk about his experience with co-founding the precision medicine company Blueprint Genetics in 2012. What started out as a technology development spinout from Stanford University, quickly grew to a global genetic testing company with >200 employees (acquired by Quest Diagnostics in 2020). With a solid background in pediatric cardiology and cardiovascular research, Tero-Pekka recently joined CardioSignal by Precordior as the Chief Medicinal Officer and General Manager of the US operations. During his talk, he will share his insights on how technology can revolutionize the medical methodology for a sustainable future and better use of resources.
Tero-Pekka Alastalo, MD, PhD, is the Chief Medical Officer and General Manager of the US operations at CardioSignal by Precordior. He also co-founded Blueprint Genetics in 2012. Tero-Pekka obtained his MD, PhD degree at the University of Turku in 2001. After 6 years of fellowships in pediatrics at the University of Turku, he pursued his postdoctoral studies at Stanford University in basic research on cardiovascular biology and disease in the Marlene Rabinovitch Lab during 2007-2009. Upon returning to Finland, he joined the University of Helsinki as a PI studying molecular and genetic mechanisms of cardiovascular diseases, as well as a pediatric cardiology fellowship. In 2012 he joined forces with fellow Stanford postdoc Samuel Myllykangas to co-found Blueprint Genetics and held various management roles including Chief Medical Officer until September 2021, when he joined CardioSignal.
Blueprint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset, the company delivers high-quality genetic testing to the global clinical community (<4000 clinicians) across 15 medical specialties. Blueprint Genetics is based in Helsinki and Seattle, with a customer base spanning over 70 countries. By combining a state-of-the-art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals, and a holistic customer experience approach, genetic knowledge is introduced to mainstream healthcare. Blueprint Genetics was acquired by Quest Diagnostics in 2020.
CardioSignal by Precordior is a scientific forerunner in the field of cardiac motion sensing, especially chest micro-rotation via micro-electromechanical sensors (MEMS) with some 30 scientific articles published in the area, including in the prestigious journals Circulation and Nature Scientific Reports. The academic research studying the heart via chest micro-motions started at the University of Turku in January 2012. Continuing this work, scientists at Precordior work today in close collaboration with researchers and cardiologists at several universities and hospitals. CardioSignal offers an easy and reliable detection of heart disease to people worldwide at an affordable price, with an application that is accurate and reliable enough to serve physicians, while easy and accessible enough to empower consumers. This is achieved via a smartphone application that transforms a phone into a device that can detect atrial fibrillation and, in the future, other heart conditions as well.
“Clinical Talks” has been renewed for yet another exciting, innovative, and enlightening season. This season will focus on sustainable innovations within Life Sciences, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations .
Season 5, will be held September 2021 until March 2022 with scheduled Talks, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.